Morgan Stanley analyst Vikram Purohit lowered the firm’s price target on Sage Therapeutics (SAGE) to $9 from $11 and keeps an Equal Weight rating on the shares after its Q3 results last week. The company’s Zurzuvae total sales of $22M were about 20% ahead of consensus and Phase II data for dalzanemdor in Huntington’s Disease remains on track to report by the end of this year, though Zuranolone will no longer be pursued in MDD- major depressive disorder – and the management intends to provide updated cash runway guidance for Sage Therapeutics in the near-term, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SAGE:
- SAGE Therapeutics Announces Strategic Reorganization Amid Executive Departures
- Sage Therapeutics price target lowered to $8 from $13 at Truist
- Sage Therapeutics price target lowered to $8 from $9 at Oppenheimer
- Sage Therapeutics price target lowered to $14 from $17 at Scotiabank
- Sage Therapeutics price target lowered to $26 from $52 at Piper Sandler
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
